Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Delpón

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Discovery Medicine|November 27, 2014
New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Pharmacotherapy|February 23, 2021
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular diseaseJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Drug Safety|April 14, 2006
The safety of digoxin as a pharmacological treatment of atrial fibrillationJuan Tamargo, Eva Delpón, Ricardo Caballero
Discovery Medicine|December 4, 2012
Drug-induced atrial fibrillation: does it matter?Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Pharmacotherapy|April 4, 2019
Pharmacotherapy for hypertension in pregnant patients: special considerationsJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Review of Clinical Pharmacology|March 9, 2023
Sex and gender differences in the treatment of arterial hypertensionJuan Tamargo, Ricardo Caballero, Eva Delpón Mosquera
Cardiovascular Research|July 1, 2010
Cardiac electrophysiological effects of nitric oxideJuan Tamargo, Ricardo Caballero, Ricardo Gómez, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 24, 2010
Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failureJuan Tamargo, Juan Duarte, Ricardo Caballero, et al.
Discovery Medicine|December 1, 2011
New therapeutic targets for the development of positive inotropic agentsJuan Tamargo, Juan Duarte, Ricardo Caballero, et al.
Expert Opinion on Investigational Drugs|April 2, 2009
I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillationJuan Tamargo, Ricardo Caballero, Ricardo Gómez, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Discovery Medicine|November 27, 2014
New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Pharmacotherapy|February 23, 2021
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular diseaseJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Drug Safety|April 14, 2006
The safety of digoxin as a pharmacological treatment of atrial fibrillationJuan Tamargo, Eva Delpón, Ricardo Caballero
Discovery Medicine|December 4, 2012
Drug-induced atrial fibrillation: does it matter?Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Pharmacotherapy|April 4, 2019
Pharmacotherapy for hypertension in pregnant patients: special considerationsJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Review of Clinical Pharmacology|March 9, 2023
Sex and gender differences in the treatment of arterial hypertensionJuan Tamargo, Ricardo Caballero, Eva Delpón Mosquera
Cardiovascular Research|July 1, 2010
Cardiac electrophysiological effects of nitric oxideJuan Tamargo, Ricardo Caballero, Ricardo Gómez, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|August 24, 2010
Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failureJuan Tamargo, Juan Duarte, Ricardo Caballero, et al.
Discovery Medicine|December 1, 2011
New therapeutic targets for the development of positive inotropic agentsJuan Tamargo, Juan Duarte, Ricardo Caballero, et al.
Expert Opinion on Investigational Drugs|April 2, 2009
I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillationJuan Tamargo, Ricardo Caballero, Ricardo Gómez, et al.
Pageof 9